Revvity

RVTY

Market cap $10.7B

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company's sustainability, social and governance strategy, initiatives and performance. This year's report, Progress with Purpose: Science and Sustainability, highlights the Company's strengthened partnerships, product innovation, sustainability driven investments and other efforts aimed at advancing science and human health responsibly. “Early in our sustainabil.

Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection, expanding its reach beyond rare diseases.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (EURONEXT: SAN and NASDAQ: SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay. T1D is a lifelong, progressive autoimmune condition that occurs when the immune system mistakenly attacks the insulin-producin.

WALTHAM, Mass.--(BUSINESS WIRE)--Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity's established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit. This new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander edit.

Revvity, Inc. (NYSE:RVTY ) Baird 2025 Global Healthcare Conference September 9, 2025 2:35 PM EDT Company Participants Stephen Willoughby - Senior VP of Investor Relations & Head of ESG Conference Call Participants Catherine Ramsey - Robert W. Baird & Co. Incorporated, Research Division Presentation Catherine Ramsey Senior Research Analyst Go ahead and get started here.

Revvity, Inc. (NYSE:RVTY ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Brandon Couillard MD & Equity Analyst All right. Good morning.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Research Triangle. The center consolidates Revvity's expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies. The new facility is staffed by R&D teams from across the organization, including soft.

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2025 Baird Global Healthcare Conference Tuesday, September 9, 2025 2:35 p.m. ET – Steve Willoughby, senior vice president, investor relations & ESG Attendees will receive an update on the Company and its strategic p.